Neuroleptic malignant syndrome is a potentially fatal drug toxicity requiring early recognition, and is distinct from malignant hyperpyrexia.
Answers are grounded in this paper and cite their sources.
Early recognition of NMS is essential during neuroleptic therapy; case reports leave distinction from malignant hyperpyrexia open to confirmation.
Two cases of neuroleptic malignant syndrome (NMS) are presented. This rare pattern of neuroleptic drug toxicity is characterised by fever, muscular rigidity, akinesia and elevated plasma creatine kinase. The condition may be fatal and early recognition is essential. Evidence is presented that NMS is unrelated to malignant hyperpyrexia.
No takes yet. Share an insight, caveat, or question.
Scarlett et al. (1983) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: